



BIO CHINA | 2026 Fusion Forward

International Convention

March 12-14, 2026 Suzhou International Expo Center

 BIOCHINA@enmore.com

About BIOCHINA

BIOCHINA 2026 (11th) will be held from **March 12–14** at the Suzhou International Expo Center.


Following the success of BIOCHINA 2025 (10th), which welcomed **30,000 attendees** in Suzhou, BIOCHINA continues its journey of boundless innovation and collaborative growth!

Over the past decade, BIOCHINA has **expanded from China's thriving biopharmaceutical sector to the world stage**, establishing an international platform for industry connectivity and uniting global expertise to advance collaboration.

Through technological breakthroughs, commercial implementation, capital support, and ecosystem integration, BIOCHINA has witnessed China's innovative drug industry evolve from following to leading, progressing alongside the industry and the times.

BIOCHINA 2026 Fusion & Forward

'Fusion' embodies the power of an ecosystem, where diverse forces converge to unlock growth. 'Forward' represents future direction, pushing boundaries to define new heights for the industry. Standing at the threshold of a new decade, BIOCHINA 2026 will join hands with global partners to step into the next golden era of China's biopharmaceutical industry.



- 30000+** Attendees
- 400+** Exhibitors
- 850+** Speakers
- 40+** Countries

About the Conference

As a flagship event in China's biopharmaceutical industry, BIOCHINA is dedicated to promoting innovation and industrial translation in the sector. Centered on innovative drugs, the conference provides a comprehensive industry platform connecting research achievements, clinical needs, industrial application, and business development, fostering the exchange of cutting-edge technologies and best practices in industrialization.

In BIOCHINA 2025, the conference invited 74 chairs, Expert Committee Members, and Conference Producers and 850 speakers, creating 204 forums, 12 closed-door meetings, 25 brainstorming sessions, and initiating 10,000+ one-on-one BiOPartnering meetings.

BIOCHINA 2026 will continue to enhance both content and organization, launching 20 inaugural forums. With industry tracks as the core focus, the conference will delve into specialized technologies, promote upstream and downstream industry collaboration, and bring together global experiences, driving efficient development of innovative drugs worldwide.



BIOCHINA 2026 (11th Edition) Agenda

| BioChina 2026 (11th Edition) Agenda | | | | | | | | | | | | |
|-------------------------------------|--------------------------------------|---|--|--|---|-------------------------------------|---|-------------------------------|--|--|--|--|
| Time | Meeting Room 9 | Meeting Room 10 | Meeting Room 11 | Meeting Room 12 | Meeting Room 13 | Meeting Room 14 | Meeting Room 15 | | | | | |
| | Small Molecule Drug Innovation Forum | | | Antibody Drug Innovation Forum | In Vivo CAR-T Innovation Forum | Exosome Innovation Forum | BioChina2026 Biomanufacturing Industry Forum | AI Innovation Forum | | | | |
| 09:00-10:00 | / Opening Panel Discussion | | / Opening Panel Discussion | | / Opening Panel Discussion | | / Opening Panel Discussion | | | | | |
| 10:00-11:00 | Mar 12 | Networking | | Networking | | Networking | | Networking | | | | |
| 11:00-12:00 | | Small Molecule Drug Innovation Forum | Nucleic Acid Innovation Forum | Antibody Drug Innovation Forum | In Vivo CAR-T Innovation Forum | Exosome Innovation Forum | BioChina2026 Biomanufacturing Industry Forum | AI Innovation Forum | | | | |
| 12:00-13:00 | | Innovation And Development Case Sharing | Bispecific/Multispecific Antibody Innovation | Clinical Development | Innovative R&D & Clinical Translation | Biopharmaceutical Aesthetics | New Drug R&D | | | | | |
| 13:00-14:00 | | | | | | | Networking | | | | | |
| 14:00-15:00 | | Networking | Networking | Networking | Networking | Networking | Networking | | | | | |
| 15:00-16:00 | | Oncology Drugs | Process And Industrialization | Innovation & Development | Clinical Development | Food Developmen | Process & Manufacturing Optimization Clinical Development | | | | | |
| 16:00-17:00 | | | | | | | Peptide Drug Innovation Forum | | | | | |
| 17:00-18:00 | | | | | | | Targets & Molecules | | | | | |
| 09:00-10:00 | Mar 13 | Small Molecule Drug Innovation Forum | XDC Drug Innovation Forum | Antibody Drug Innovation Forum | In Vivo CAR-T Innovation Forum | Cell Therapy Innovation Forum | BioChina2026 Biomanufacturing Industry Forum | Peptide Drug Innovation Forum | | | | |
| 10:00-11:00 | | Autoimmune Diseases | Process Development and CMC | Bispecific/Multispecific Antibody Innovation | Process & Quality | Future Manufacturing | Agricultural Innovation | | | | | |
| 11:00-12:00 | | | | | | | Networking | | | | | |
| 12:00-13:00 | | Small Molecule Drug Innovation Forum | XDC Drug Innovation Forum | Antibody Drug Innovation Forum | In Vivo CAR-T Innovation Forum | Cell Therapy Innovation Forum | Peptide Drug Innovation Forum | | | | | |
| 13:00-14:00 | | | | | | | Targets & Molecules | | | | | |
| 14:00-15:00 | | Networking | Networking | Networking | Networking | Networking | Networking | | | | | |
| 15:00-16:00 | | CNS | Process Development And CMC | Bispecific/Multispecific Antibody Innovation | Commercialization | Autoimmune Disease Drug Development | Biopharmaceutical Aesthetics | | | | | |
| 16:00-17:00 | | | | | | | Indication Development | | | | | |
| 17:00-18:00 | | | | | | | Networking | | | | | |
| 09:00-10:00 | Mar 14 | Small Molecule Drug Innovation Forum | XDC Drug Innovation Forum | Antibody Drug Innovation Forum | Stem Cell Therapeutics Innovation Forum | Cell Therapy Innovation Forum | BioChina2026 Biomanufacturing Industry Forum | Peptide Drug Innovation Forum | | | | |
| 10:00-11:00 | | Anti-infectives Metabolic Therapeutics | Differentiated Targets And Molecular Design | Upstream & Downstream Process Optimization | New Indications & Drugability Exploration | Solid Tumor Drug Development | Food Development | | | | | |
| 11:00-12:00 | | | | | | | Process & Commercialization | | | | | |
| 12:00-13:00 | | Cardiovascular Therapeutics | | | | | Networking | | | | | |
| 13:00-14:00 | | | | | | | Networking | | | | | |

About the Conference- Speaker

| Track | Company | Name | Job Title |
|---------------------|---|--------------------------|---|
| ADC | Bridge Biotherapeutics (Hangzhou) Co., Ltd. | Wei Ziping | Co-Founder, Chairman & CEO |
| ADC | Fosun Kite Biotech Co., Ltd. | Yang Xiaoming | Chief Technology Officer (CTO) |
| ADC | RemeGen | Zichen Qian | Director of Process Development |
| ADC | Multitude Therapeutics | Yan Jiaqing | Senior R&D Director |
| AI | XtalPi | Dr. Lipeng Lai | Co-founder and Chief Innovation Officer |
| AI | Insilico Medicine | Feng Ren | Co-CEO & CSO |
| Antibody | Innovent Biologics | Manyang Lin | Senior Director of Engineering Projects |
| Antibody | Process Development | Dongmei Han | General Manager |
| Antibody | Harbour BioMed | Terry Lu | Quality Director |
| Antibody | Qilu BioPharma | Ding Liu | Deputy General Manager |
| Antibody | Qilu Pharmaceutical Company | Yan Fang | Senior Director |
| Antibody | Shanghai Langrun Mabwell Biomedical Technology Co., Ltd. | An Wang | Quality Head |
| Antibody | 3d-medicines | Charles Feng | Executive Director of Large Molecule CMC, Head of MAH Production Management |
| Antibody | Shanghai Huaota Biopharmaceutical Co., Ltd. | Cui Xiaopei | Senior Director of Technical Department |
| Antibody | Halobio | Bao Yanwen | Deputy Director (Upstream Process) |
| Antibody | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | Xianghai Cai | Vice President |
| Antibody | Shanghai Hengrui Pharmaceuticals Co, Ltd. | Zhou Kaimeng | Vice General Manager |
| Antibody | Cytocares | Yingfeng Huang | CEO |
| Antibody | BioRay Pharmaceutical Co., Ltd. | Zhu Wei | Chief Medical Officer (CMO) |
| Antibody | Antengene | Hou Bing | Executive Director of Early Drug Development |
| Antibody | Shanghai Mabgeek Pharmaceutical Co.,Ltd | Yuan | Director of Production and Quality Management |
| Antibody | Jiangsu T-mab Biopharmaceutical Co., Ltd | Dai Hu | Head of Quality & QP |
| Antibody | Junshi BioEngineering | Homer Zhang | Senior Director of Automation & Information |
| Antibody | Elpisience | Andy Yang | RA Head, Director |
| Antibody | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Yubin Zhou | Vice President of Clinical Operations |
| Antibody | EpimAb Biotherapeutics, Inc. | Wu Xuan | Senior Director of Biotechnology Department |
| Antibody | INSTIL BIO (U.S.-based biotech company) | Lu YingQi | China CMO/SVP |
| Antibody | Shanghai Huaota Biopharmaceutical Co., Ltd. | Xiangyang Zhu | CEO |
| Antibody | BioRay Pharmaceutical Co., Ltd. | Dr. Haibin Wang | CEO |
| Antibody | HanchorBio Inc | Scott Liu, Ph.D. | Founder, Chairman, and CEO |
| Antibody | Gmax Biopharm LLC. | SHUQIAN JING | Founder, Chairman&CEO |
| Antibody | 3D Medicine Inc | Carol Xia | VP & Board secretary |
| Antibody | Innolake Biopharm | Dr. Mingde Xia | Founder, Chairman, and CEO |
| Antibody | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Wenzhi Tian | Chairman, CEO and CSO |
| Antibody | WUHAN YZY BIOPHARMA CO., LTD. | Dr. Zhou Pengfei | Founder& Chairman &CEO |
| Antibody | CStone Pharmaceuticals | Dr. Jason YANG, MD, PhD. | CEO, President of R&D and Executive Director of the Board |
| Antibody | Biosion Inc. | Mingjiu Chen, PhD | Founder, President & CEO |
| Biomanufacturing | Innovation Academy for Precision Measurement Science and Technology | Lichun He | Professor and Ph.D. Supervisor |
| Bispecific Antibody | Novatim | Dr. Guoxiang Wu | Founder, Chairman and CEO |
| Cell Therapy | FOSUNKAIROS | WENGSHI WANG | SVP |
| Cell Therapy | Juventas Cell Therapy Ltd. | Wang Yongzeng | Chief Technology Officer (CTO) |
| Cell Therapy | Imunopharm Technology Co. Ltd. | Qi Feifei | Cofounder & CTO |
| Cell Therapy | Shanghai Cell Therapy Group | Gao Haixia | Senior Director of Supply Chain |
| Cell Therapy | JW Therapeutics Ltd. | Ivan Lin | Head of Manufacturing/Head of MSAT&ATS |
| Cell Therapy | Simcere | Shuping Fang | Director |
| Cell Therapy | Leman Biotech | Dudu Tong | Executive Director |
| Cell Therapy | PRECISION BIOTECH | MEILING WANG | QC Lead |

About the Conference- Speaker

| Track | Company | Name | Job Title |
|----------------------|---|------------------------|---|
| Cell Therapy | Xinghua Bio | Hua Liu | Founder & Chief Scientific Officer |
| Cell Therapy | PersonGen BioTherapeutics(Suzhou) Co.,Ltd. | Fengtao You | Director Innovative drug research Institute |
| Cell Therapy | NaviGen Bio | Meijia Yang, PhD | Founder and Chairman |
| Cell Therapy | Nanjing Acrolimmune Biopharmaceutical Co. Ltd | Mingyang Gu | General Manager Assistant |
| Cell Therapy | PersonGen | Min Wang | VP |
| Cell Therapy | Base Therapeutics (Shanghai) Co, Ltd. | Lv Fenghua | Senior Director of CMC and Head of Quality |
| Cell Therapy | GRACELL | LJ Shen | SVP |
| Cell Therapy | Origincell Therapeutics | He Xiaowen | CSO |
| Cell Therapy | Bangyao Biotechnology Co., Ltd | Liang Su | Manufacturing Director |
| Cell Therapy | Univell Biotech | Alex Wu | CMC sVP |
| Cell Therapy | AbelZeta | DONGYAO NI | MD SVP, GLOBAL BD & LICENSING AND CORPORATE AFFAIRS |
| Cell Therapy | Sino-cell Biomed Co., Ltd | Xinhua Zhang | VP of Quality |
| Cell Therapy | HRYZ Biotech Co. | Yanyan Han | CSO |
| Cell Therapy | Simnova | Wen Limin | SVP |
| Cell Therapy | Fosun Kairos | Xingrong Chen | CEO |
| Cell Therapy | Neukio Biotherapeutics | Wang Ligun | CEO |
| Cell Therapy | PersonGen BioTherapeutics (Suzhou) Ltd., Co. | Lin Yang | Founder/Chairman/CEO |
| CGT/Antibody | Zhejiang Provincial Drug Inspection Center | Tu Bing | Biological Products Inspector |
| Clinical | Zhongshan Hospital, Fudan University | Xiaowu Huang, PhD & MD | Director of the Biotherapy Center, Professor and Chief Physician of Hepatobiliary Oncology and Liver Transplantation, Zhongshan Hospital, Fudan University; |
| Clinical | Doma Biopharmaceutical (Suzhou) Co., Ltd. | Dr Rong Chen | Chief Medical Officer |
| Exosome | NewExo Biotechnology Co., Ltd | Haoran Wang | CEO |
| Exosome | Echo Biotech Co., Ltd, Beijing | Libo Zhao | Chief Technology Officer & Co-founder |
| Exosome | Shandong Qilu Cell Therapy Engineering Technology Co., Ltd. | SHUANGSHUANG YANG | R&D Project Manager |
| Exosome | Tingo Exosomes Technology Co.,Ltd | Xiaohu Ge | Chairman |
| Gene Therapy | Kanglin Biotech | XUDONG ZHU | Quality Director |
| Gene Therapy | Exegenesis Bio Inc. | Zhenhua Wu | Founder and CEO |
| Investment & Finance | OrbiMed | Daniel Ying | Executive Director |
| MNC | Gilead Sciences Shanghai Pharmaceutical Technology Co., Ltd | Zig LANG | Vice President and Head of International Medical Affairs and APAC Oncology Development, China Development Site Head |
| mRNA | Suzhou HealiRNA Biotechnology Co.,Ltd. | Zhong Chen | VP |
| Nucleic Acid | Triction Biotherapeutics. Inc | Li ShiYou | Co-founder/CTO |
| Nucleic Acid | Axter Therapeutics | Sunny Huang | VP |
| Nucleic Acid | Shanghai Huanma Biopharmaceutical Co., Ltd. | Yang Yun | Chairman&CTO |
| Nucleic Acid | Theorna | Lin Qingshu | CMC Director |
| Nucleic Acid | Ningbo Vigor Biologics Inc | Changyun Xiong | CEO |
| Nucleic Acid | WestGene Biopharma | Xiangrong Song, | CEO & Scientific Co-founder |
| Nucleic Acid | CirCode Biomed | Dr. Chenxiang Tang | CEO |
| Nucleic Acid | Abogenbio | Dr. Bo Ying | Founder, Chairman and CEO |
| Nucleic Acid | Youjia (Hangzhou) Biomedical Technology CO.,LTD | Lulu Fu | Director of Pharmaceutical Formulations |
| Peptide | Shanghai Minwei Biotechnology Co.,LTD | Wen-Xin Song | Deputy general manager |
| Peptide | Coherent Biopharma (Suzhou) Co., Ltd. | Jun Shao | Chief Technology Officer |
| Peptide | Shenzhen ScienCare Pharmaceutical Co., Ltd | Vincent Qu | Chief Technology Officer |
| Peptide | Shenzhen Sungening Biologicals Ltd. | Chester Yuan | Co-Funder/CSO |
| Peptide | Gan & Lee Pharmaceuticals | Wei Chen | Chairman, President, and Chief Executive Officer |
| Peptide | The United Laboratories | Cao Chunlai | General Manager |
| Peptide | Hangzhou Jiuyuan Gene Engineering Co.,LTD | Wang Tongying | Technical Director |
| Peptide | VISEN Pharmaceuticals | Jing Zhu | CMC VP |
| Peptide | Fosun Pharma Global R&D | Song Yang | Vice President, Head of CNS & Immunology |

About the Conference- Speaker

| Track | Company | Name | Job Title |
|-------------------------|--|-----------------------|--|
| Pharma | Sino Biopharmaceutical Limited | Mr. Tse Hsin | Executive Director, Senior Vice President, Member of the Executive Board Committee |
| Pharma | Qilu Pharmaceutical | Tao Weikang | Director, Vice President, and General Manager of Global Innovation R & D System of Qilu Pharmaceutical Group |
| Polyclonal Antibody/ADC | VelaVigo | Li Jing | Founder and CEO |
| Radiopharmaceutical | BoomRay | Bo Shan | Chief Executive Officer (PhD) |
| Radiopharmaceutical | Shanghai Institute of Materia Medica Chinese Academy of Sciences | Zhen Cheng | Professor and Director of Molecular Imaging Center |
| Radiopharmaceutical | Chengdu StarRay Therapeutics Co., Ltd | David Chen | President&CSO |
| Radiopharmaceutical | BoomRay Pharmaceutical Co., Ltd. | Andy | QA Assistant Director |
| Research & Government | Shanghai Institute for Drug Control (SIFDC) | CHEN GANG | Chief Pharmacist |
| Small Molecule | AstraNeura, Co., LTD. | Xianbo Zhou | Founder&CEO |
| Small Molecule | Synrx | HU HE | VP |
| Small Molecule | Degron Therapeutics Inc. | Lily Zou | Co-Founder and CEO |
| Small Molecule | Fosun Pharma / Novaonco Co., Ltd. | YU XIAOHONG | Co-CSO / Chairman |
| Small Molecule | IRCBC, SIOC, Chinese Academy of Sciences | Yelin Chen | Principal Investigator |
| Small Molecule | JOYO Pharma | Lei Li | Senior Director of PPM |
| Small Molecule | HKUST / EnKang Pharmaceuticals (Guangzhou) ,Ltd. | Prof. LIANG Chun | Founder & CSO |
| Small Molecule | Signet Therapeutics | Zhang Haisheng, Ph.D. | Founder and CEO |
| Small Molecule | Shanghai CureGene Pharmaceutical Co. | Xiaowu Chen | Vice President, Chemistry |
| Small Molecule | HaiHe Pharmaceuticals Inc. | Fugen Li | SVP (Translational Medicine) |
| Small Molecule | CGeneTech(Suzhou,China)Co.,Ltd. | Jiahong Zhao | CMO |
| Small Molecule | Allorion Therapeutic | Zhen Liu | VP |
| Small Molecule | Pfizer (China) Research and Development Co., Ltd. | MENG QIAO | Director |
| Small Molecule | Evopoint Biosciences Co., Ltd | Fred Hu, Ph.D. | CTO, Co-Founder |
| Small Molecule | Phaeno Therapeutics | Qin Donghui | Chairman & CEO |
| Small Molecule | Ranok Therapeutics(Hangzhou) Co., Ltd. | WEIWEN YING | CEO |
| Small Molecule | Salubris Pharmaceuticals | Jane Wang | CSO |
| Small Molecule | Degron Therapeutics | Julia Dou | Director |
| Small Molecule | Haihe Biopharma | Dr. Guo Xiaoning | CMO |
| Small Molecule | NeuShen Therapeutics | Joan (Huajiong) Shen | Founder and CEO |
| Small Molecule | CGeneTech(Suzhou,China)Co.,Ltd. | John Yu | CEO |
| Sourcing | Remegen.cn | jinxia jia | Executive Director (Supply Chain Management Department) |
| Stem Cell | HELP Therapeutics | S | Co-founder&CTO |
| Stem Cell | Nuwacell Biotech Co., Ltd. (Guangzhou, China) | Dong Chengyou | GM Assistant |
| Stem Cell | Qilu Cell Therapy | Tan Yi | VP and R&D Director |
| Stem Cell | Hangzhou Institute for Advanced Study, UCAS | Cheguo Cai | Vice Dean for School of Life and Health Sciences |
| Stem Cell | HemaCell Biotechnology Inc. | Fangfang Zhu | CEO |
| Stem Cell | HELP Therapeutics | YONGSHENG XU | Co-founder&CTO |
| Stem Cell | Nuwacell Biotech Co., Ltd. (Guangzhou, China) | Dong Chengyou | GM Assistant |
| Stem Cell | Qilu Cell Therapy | Tan Yi | VP and R&D Director |
| XDC | MediLink Therapeutics | Tony Xue | Chairman & CEO |
| XDC | - | Ziping Wei | Co-founder, Chairman, and CEO |
| Small Nucleic Acid | Youjia Bio | Zhao Chengjiang | Director of the Nucleic Acid Drug Research Institute |
| Small Nucleic Acid | ChainGen Bio | Xuefeng Zhang | Co-founder & COO |
| Small Nucleic Acid | Visirna Therapeutics | You Dong | Head of Clinical Development |
| Small Nucleic Acid | Haichang Biotech | Bai Jun | Head of Small Nucleic Acid Department |
| Small Nucleic Acid | AnlongBio/AnlongMed | Chunlin Zhao, Ph.D | Founder |
| Small Nucleic Acid | Youjia Bio | Cui Wenhao | CEO |
| Other Areas | China Insights Consultancy (CIC) | Glenn (Xuchao) Hou | Founding Partner |

BIOCHINA2026 Main Forum

| Date | March 12th | March 13th |
|-------------------|--|--|
| | 09:00-09:20 BIOCHINA Opening Ceremony 09:20-10:00 BIOCHINA Opening Speech | 09:00-11:00 MNC Strategy Release |
| 09:00-14:00 | 9:40-10:40 Panel Discussion: Disruptive Innovation – Global Insights 10:40-11:10 Presentation: Biotech Opportunities In The AI Era 11:10-11:40 Presentation: Biotech Innovation From Clinical Practice | 11:00-12:00 Panel Discussion: Co-Creating a Collaborative Ecosystem with Global Partners |
| | 11:40-12:00 BIOCHINA Awards | 12:00-13:00 Strategic Release |
| | 12:00-12:50 Panel Discussion: AI in Biopharma 12:50-13:40 Panel Discussion: How Can Chinese Pharma Companies Embrace Globalization? | 13:00-14:00 Strategic Release |
| Concurrent Events | March 12, 18:00–20:00 BIONIGHT 2026 (Invitation Only) March 12–14 BiOPartnering 1V1 Meetings March 12–14 BIOCHINA2026 Exhibition | |

| BIOCHINA2026 BioBD Forum | | BIOCHINA2026 BiOFUNDING Forum | BIOCHINA2026 Global IP Forum |
|--------------------------|---|--|---|
| Date | March 12th | March 13th | March 14th |
| 09:00-11:00 | Exhibition Hall Closed During Opening Ceremony | BiOFUNDING Forum 09:00-09:20 Presentation: Global Biopharma Investment Trends 09:20-10:10 Panel Discussion: 2026 Key Themes in Biotech Investment 10:10-11:00 Panel Discussion: How China's Dual-Currency Healthcare Funds Invest Overseas | 09:00-11:00 Compliance-Driven Value: Tax & Legal Strategies for Biopharma Companies |
| 11:00-12:00 | Lunch & Networking | Lunch & Networking | |
| 12:00-14:00 | BD Strategy 12:00-12:30 Presentation: Insights On BD Deals For Chinese Innovative Drugs And Global Enablement 12:30-13:15 Presentation: MNC Asia-Pacific Strategy 13:15-14:00 Presentation: Global Strategies Of Chinese Big Pharma & Biotech <small>Speaker: Vivian Feng, Business Development Department General Manager, Shanghai Fosun Pharmaceutical (Group) Co., Ltd</small> | 12:00-13:00 LP-GP-Biotech Ecosystem: Aligning Policy, Capital, and Innovation 13:00-14:00 Pharma Incubators: Innovation Outposts and Win-Win Models | |
| 14:00-15:00 | Networking & Events | Networking & Events | |
| 15:00-18:00 | Market Outlook 15:00-16:00 NewCo Evolution & MNC-China Collaboration 16:00-16:40 China Market: New Opportunities & Strategies 16:40-17:20 Global Expansion: China's Innovation Pathways 17:20-18:00 Reimbursement Strategies for Innovative Drugs | 15:00-16:00 Industry Investment Outlook: Alliances and Strategic M&A 16:00-17:00 After the Boom: Value Reset in the IPO 2.0 Era 17:00-18:00 Back to the Source of Innovation: Investing Early, Small, and New | |

BIOCHINA2026 Global Forum

| Date | March 12th | March 13th | March 14th |
|-------------------|---|---|--|
| 09:00-11:00 | Exhibition Hall Closed During Opening Ceremony | Global Market 09:00-09:10 Opening Presentation 09:10-09:50 Pharma Strategic Alliance Panel 09:50-10:50 CGT Panel | Middle East Market 9:00-9:30 Panel Discussion : Regional Regulations, market entry strategies, and pharma business development in Middle East LATAM Market 10:00-10:30 Panel Discussion: Focus Business Development, Licensing, and Collaboration Opportunities with Latin American Pharma Companies 10:30-11:00 panel Discussion: Clinical & Supply Chain Opportunities |
| 11:00-12:00 | Lunch & Networking | Lunch & Networking | Lunch & Networking |
| 12:00-14:00 | Korea Market 12:00-12:20 Opening Keynote Presentation – Highlight Capital Speaker: Lee, Highlight Capital, Principle 12:20-13:20 Panel Discussion – China-Korea Collaboration Opportunities Speaker: Lee, Highlight Capital, Principle Open Innovation Center, Celltrion Inc Hun Kim, SK Bioscience, President Soyong Jang, R&D Business Development Director, Celltrion Inc 13:20 – 14:00 Panel Discussion – Pharma Market Access and Regulatory Strategies | LATAM Market 12:00-13:00 Panel Discussion: Focus Business Development, Licensing, and Collaboration Opportunities with Latin American Pharma Companies Speaker: Joao Siffert, Eurofarm, Head of R&D, CEO, Director. Middle East Market 13:00-13:20 Keynote Presentation – Middle East Ecosystem Landscape 13:20-14:00 Panel Discussion: Regional Regulations, market entry strategies, and pharma business development in Middle East Speaker: Lulu Manasseer, Alnylam Pharmaceuticals, Inc, Business Consultant and Principal Associate Scientist. Joe Henein, NewBridge Pharmaceuticals | Emerging Market 09:00-10:00 Panel Discussion- Emerging regions & Belt & Road Collaboration Clinical , Production & Supply Chain Opportunities in emerging Belt & Road Regions Speaker: Dr. Obaidullah, phd, Drug Regulatory Authority of Pakistan(DRAP), CEO. Dr. Akhtar Abbas khan, National Pharmacovigilance Center, Drug Regulatory Authority of Pakistan(DRAP), Director of Pharmacy Services & Head. Southeast Asian Market |
| 14:00-15:00 | Networking & Events | Networking & Events | |
| 15:00-18:00 | Korea Market 15:00 – 15:40 Panel Discussion – Biotech Collaboration: BD and Co-development Models Speaker: Nam-Gu Her, AIMED BIO, CEO Nari Yun, GI INNOVATION, Vice president India market 16:00-16:20 Keynote Presentation 16:20-17:20 Panel Discussion – BD Collaboration between China and India Speaker: Mayur Sangwai, Dr. Reddy's Laboratories, Head BD - Innovation Licensing. Manoj Thombare, Sun Pharma Laboratories Ltd, Senior General Manager and Business Development & Licensing. 17:20-18:00 Panel Discussion – Supply Chain Collaboration between China and India Speaker: Dr. SAMBASHIVA D, Abhignya Biotech Pvt Ltd, Founder. | Russia Market 15:00-15:20 Opening Remarks 15:20-16:20 Panel Discussion- BD & Licensing Announcements Speaker: Alexander Nozdrachev, BinnoPharma, Managing Partner of Innovant Bio. Svetlana Bolsheva, BinnoPharma, Strategy & Business Development Director. Vera Mymirna, Geropharma, BD specialist Business Development. Alexandr Gorynin, Nanolek, BD AND M&A director, Nizhpharm Artem Ahn, BD and Strategy Director. Igor Borisenko, R-pharm, Retail Director. 16:20-17:20 Innovation and Supply Chain collaboration 17:20- 17:40 Q&A | |
| Concurrent Events | March 12th-14th BIOCHINA2026Exhibition March 12th 18:00-20:00 BIONIGHT 2026 (Invite-only) | March 12th-14th BiOPartnering 1V1Meetings March 13th18:00-20:00 Networking Reception | 8 |

| BIOCHINA2026 Global Regulatory Forum | | BIOCHINA2026 Global Clinical Forum | BIOCHINA2026 Formulation Innovation Forum |
|--------------------------------------|---|--|--|
| Date | March 12th | March 13th | March 14th |
| 09:00-11:00 | Exhibition Hall Closed During Opening Ceremony | <p>Post-BD Clinical Strategy 09:00–10:00 Panel Discussion: Global Clinical Pathways For Chinese Innovative Drugs – Post-License Out Strategies And Collaboration 10:00–10:30 Presentation: TBC 10:30–11:00 Presentation: TBC</p> | <p>Large Molecule Formulations 09:00–10:00 ADC Subcutaneous Formulation Case Sharing 10:00–11:00 ADC Lyophilized Formulations</p> |
| 11:00-12:00 | Lunch & Networking | Lunch & Networking | Lunch & Networking |
| 12:00-14:00 | <p>US & European Markets 12:00–13:00 United States 13:00–14:00 Europe</p> | <p>Global Multi-Region Clinical Development 12:00–12:20 Presentation: Clinical Submission Strategies Across Multiple Regions 13:00–14:00 Panel Discussion: Global Clinical Strategy For Chinese Innovative Drugs Innovative Therapy Clinical Models 13:00–13:20 Presentation: TBC 13:20–14:00 Panel Discussion: How IIT Studies Can Accelerate Approval And Serve As Catalysts For Innovative Therapies</p> | <p>Large Molecule Formulations Formulation Development Case Sharing 12:00–12:20 Presentation: Antibody Subcutaneous Formulation Development High-Concentration/Ultra-High-Concentration Antibody Formulations</p> |
| 14:00-15:00 | Networking & Events | Networking & Events | <p>Formulation Process And Manufacturing 14:00–15:00 Formulation Process Optimization 15:00–16:00 Formulation Process Manufacturing</p> |
| 15:00-18:00 | <p>APAC & Emerging Market Regulations 15:00–16:00 Global 16:00–17:00 Indonesia 17:00–18:00 Saudi Arabia</p> | <p>Overseas Projects China Clinical Development Strategy 15:00–16:00 China Market Characteristics And Clinical Strategies 16:00–17:00 Case Studies Of Overseas Projects In China Clinical Development 17:00–18:00 Collaboration Models And Risk Management</p> | |

BIOCHINA2026 Global Supply Chain Forum

BIOCHINA2026 Global Key Indication Forum

Date

March 12th

| | | | |
|-------------|---|--|--|
| 09:00-11:00 | Exhibition Hall Closed During Opening Ceremony | Neurological Diseases 09:00-10:00 R&D 10:00-11:00 CNS From A Clinical Perspective | Infectious Diseases 09:00-10:00 R&D 10:00-11:00 R&D |
| 11:00-12:00 | Lunch & Networking | | |
| 12:00-14:00 | Global Supply Chain Development 12:00-13:00 Overseas Supply Chain Compliance 13:00-14:00 Overseas Supply Chain Development | Ophthalmic Diseases 14:00-15:00 R&D 15:00-16:00 Clinical | Metabolic Disease Drugs 12:00-13:00 R&D 13:00-14:00 Clinical |
| 14:00-15:00 | Networking & Events | | Autoimmune Disease Drugs 14:00-15:00 R&D 15:00-16:00 Clinical |
| 15:00-18:00 | Local Supply Chain Development 15:00-16:00 Cost Reduction and Efficiency Improvement Speaker: Gao Haixia, Senior Director of Supply Chain, Shanghai Cell Therapy Group 16:00-17:00 Local Substitution 17:00-18:00 Supply Chain Stability | Oncology Drugs 15:00-16:00 R&D 16:00-17:00 Clinical 17:00-18:00 Industry | |

BIOCHINA2026 Immunology Innovation Forum

BIOCHINA2026 University
Technology Transfer Forum

| Date | March 12th | March 13th | March 14th |
|-------------|--|--|--|
| 09:00-11:00 | Exhibition Hall Closed During Opening Ceremony | 09:00-11:00 Tumor Immunology | 09:00-11:00 University Translation Strategy & Top-Level Design Why University Translation Is The Lifeline Of Life Sciences Building The “Highway” For Translating Academic Achievements Clinical-Driven Innovation: The Fast Track For Translation |
| 11:00-12:00 | Lunch & Networking | Lunch & Networking | Lunch & Networking |
| 12:00-14:00 | 12:00-14:00 Infection & Immunology | 09:00-11:00 Tumor Immunology | 12:00-14:00 Diversified Collaboration Models Pros, Cons, And Practical Use Of Option-to-License Models Sustainable Approaches To Joint Labs And Innovation Centers Which Collaboration Model Fits Your Stage Best? 14:00-16:00 Avoiding Pitfalls & Maximizing Value “Devil In The Details” In Technology Transfer Contracts Identifying “Good Projects” And “Good Deals” From Scientist And Investor Perspectives Mapping A New Blueprint For Efficient Life Science Translation In China |
| 14:00-15:00 | Networking & Events | Networking & Events | |
| 15:00-18:00 | 15:00-18:00 Autoimmune Diseases | 15:00-18:00 Immunodeficiency Diseases | |

| BIOCHINA2026 Radiopharmaceutical Innovation Forum | | BIOCHINA2026 CMC Going Global Forum | BIOCHINA2026 Global Tech Transfer & Compliance Forum |
|---|--|---|---|
| Date | March 12th | March 13th | March 14th |
| 09:00-11:00 | Exhibition Hall Closed During Opening Ceremony | US and EU Markets 09:00-10:00 CMC Global Registration Strategies: FDA/EMA Submissions And Pharmaceutical Documentation 11:00-12:00 CMC Regulatory Review, Approval, And Audits | Commercial Manufacturing: Large-Scale Antibody Production / Multi-Product Co-Processing 09:00-09:20 Presentation: TBC 09:20-09:40 Presentation: Large-Scale Production Insights Commercial Manufacturing & Inspection 10:00-10:20 Presentation: Addressing Pre-Commercialization Challenges From Process Validation 10:20-10:40 Presentation: Data Integrity And Case Studies In Domestic Manufacturing Inspections 10:40-11:00 Presentation: Contamination Control Strategies From Validation Management Perspective |
| 11:00-12:00 | Lunch & Networking | Lunch & Networking | Lunch & Networking |
| 12:00-14:00 | Advanced Technologies & Target Breakthroughs 12:00-13:00 Technology Breakthroughs 13:00-14:00 Collaborative Innovation | Emerging Markets 12:00-13:00 Belt & Road / Southeast Asia: Regulatory Submissions And CMC Oversight 12:00-12:20 Presentation: Going Global – UAE 13:00-14:00 Presentation: Regulatory Submission & CMC Requirements in Global & Korea | Regulatory Submissions: Domestic & International Strategies 12:00-12:20 Presentation: Global Submission Strategies – China, US & EU 12:20-12:40 Presentation: Pharmaceutical Changes During Clinical Trials & Coordinated Submissions in China, US & Australia 12:40-13:00 Presentation: Smart Submissions: AI Applications And Regulatory Considerations From IND To NDA 13:00-14:00 Panel Discussion: Managing Domestic And International Pharmaceutical Submissions And Changes |
| 14:00-15:00 | Networking & Events | Networking & Events | Manufacturing Engineering & Smart Manufacturing 15:00-15:20 Presentation: Smart Biopharmaceutical Factories 15:20-15:40 Presentation: ADC Facility Development Insights 15:40-16:00 Presentation: Facility Strategy – From Assessment to Construction GMP Compliance: FDA / EMA / NMPA Case Studies: Implementing Smart Manufacturing in Biologics |
| 15:00-18:00 | R&D Process Development & Industrialization 15:00-16:00 Early Development Innovations Alpha-Emitter Early R&D Radiopharmaceutical Ligand Development 16:00-17:00 CMC & Commercial Manufacturing 17:00-18:00 Clinical PI Face-to-Face | BIOCHINA2026 Global Tech Transfer & Compliance Forum <p>Global Quality & Compliance: International Standards and Compliance Systems</p> 16:00-16:20 Presentation: Quality Insights 16:20-16:40 Presentation: Differences in Antibody Drug Quality Standards from IND to BLA 16:40-17:00 Presentation: Quality Research Quality Change Management & Technology Transfer 17:00-17:20 Presentation: Lifecycle Change Management 17:20-17:40 Presentation: Post-Market Quality Changes 17:40-18:00 Presentation: TBC | |

BIOCHINA2026 Innovative Process Technology Forum

| Date | March 12th | March 13th | March 14th |
|-------------|---|--|--|
| 09:00-11:00 | Exhibition Hall Closed During Opening Ceremony | Purification Forum Virus Clearance Post-Marketing Process Changes And Compliance 10:00–10:20 Presentation: TBC 10:20–10:40 Presentation: Chromatography Media Related | Cell Culture Forum Cell Line Development And Expression System Optimization 9:00–9:20 Presentation: Cell Line Development Related 3D Cell Culture And Construction Establishment And Validation Of Cell Culture Models Cell Culture Quality And Compliance |
| 11:00-12:00 | Lunch & Networking | Lunch & Networking | Lunch & Networking |
| 12:00-14:00 | Quality Analysis ADC Full Lifecycle Quality Control System Establishment 12:00–12:20 Presentation: ADC Drug Quality Research 12:20–12:40 Presentation: ADC Quality Method Validation 13:00–14:00 Quality Analysis – Agilent Special Session | Analytical Testing Innovation And Advanced Applications In Testing 12:00–12:20 Presentation: Antibody Quality Control Techniques 12:20–12:40 Presentation: Process Residuals Quality Control And Analysis Strategies Lifecycle Testing Compliance And Validation 13:00–14:00 Panel Discussion: Antibody Analytical Method Development And Validation Under The New Chinese Pharmacopoeia With Case Sharing | Cell Culture Forum 12:00–13:00 Scale-up of Cell Culture Processes 13:00–14:00 Large-Scale Cell Culture Technologies and Applications |
| 14:00-15:00 | Networking & Events | Networking & Events | Cleanroom And Engineering Equipment Forum 14:00–15:00 Quality Assurance System For Cleanroom Engineering And Equipment 15:00–16:00 Digitalization And Efficiency Optimization Of Engineering Equipment |
| 15:00-18:00 | Purification Forum HCP Impurity Removal Biologics Separation And Purification Technology Purification Process Characterization Development And Scale-Up Of Biologics Purification Processes | Pharmaceutical Excipients, Packaging And Delivery Innovation In Delivery Systems 15:00–15:20 Presentation: Functionality And Clinical Safety Of Inhalation Delivery Devices 16:00–17:00 Compatibility And Compliance 17:00–18:00 Development And Application Of Novel Biologics Excipients | |

BIOCHINA2026 Small Molecule Drug Innovation Forum

BIOCHINA2026 Innovative Nucleic Acid Drugs Forum

| Date | March 12th | March 13th | March 14th |
|-------------|---|--|--|
| 09:00-11:00 | Exhibition Hall Closed During Opening Ceremony | CMC and Analytical Method Development 09:00-10:00 Case Sharing: Small Molecule Autoimmune Innovative Drug Development | mRNA Development Case Sharing 09:00-10:00 Case Studies in mRNA Vaccine Development 10:00-11:00 Case Studies in mRNA Drug Development |
| 11:00-12:00 | Lunch & Networking | Lunch & Networking | Lunch & Networking |
| 12:00-14:00 | Breakthroughs and Challenges of “Undruggable” Targets 12:00-13:00 Case Sharing: Small Molecule Oncology Innovative Drug Development | Small Molecule Formulation Improvement & Solubility Enhancement Innovations | mRNA Delivery and CMC 12:00-13:00 Delivery Optimization 13:00-14:00 CMC Strategies |
| 14:00-15:00 | Networking & Events CIP Protein Degradation Technology 15:00-16:00 Panel Discussion: Overcoming “Undruggable” Targets 16:00-16:20 Presentation: Non-Protein Degradation Molecules 16:20-16:40 Presentation: Protein Degradation Molecules 16:40-17:00 Presentation: Protein Degradation Molecules | Networking & Events Tumor & Autoimmune Drug Development Case Studies 15:00-16:00 Clinical-Driven Autoimmune Drug Development 16:00-17:00 Innovative Targets & Molecules for Small Molecule Oncology Drugs Process Validation & Commercial Production | Circular RNA 14:00-15:00 Circular RNA Design and CMC Nucleic Acid Conjugates 15:00-16:00 Nucleic Acid Conjugate Development |

BIOCHINA2026 Nucleic Acid Innovation Forum

BIOCHINA2026 XDC Drug Innovation Forum

| Date | March 12th | March 13th | March 14th |
|-------------|--|---|---|
| 09:00-11:00 | Exhibition Hall Closed During Opening Ceremony | <p>Process Development and CMC 9:00–10:00 Panel Discussion: From China to the World – ADC CMC Development Strategies and Global Expansion</p> <p>ADC Process Characterization and Validation 10:00–10:20 Presentation: TBC 10:20–10:40 Presentation: CMC Studies of Bispecific ADCs 10:40-11:00 Presentation: TBC</p> | <p>Differentiated Target and Molecule Design ADC Autoimmune Track 9:00–9:20 Presentation: ADC Development And Clinical Progress In Autoimmune Diseases</p> <p>Bispecific/Toxin ADC Development 10:00–10:20 Presentation: Bispecific Toxin ADC Development</p> |
| 11:00-12:00 | Lunch & Networking | Lunch & Networking | Lunch & Networking |
| 12:00-14:00 | <p>Innovation And Development Case Sharing Small Nucleic Acid Clinical Development 12:00–12:20 Presentation: siRNA Drug Clinical Development Strategies And Clinical Data Overview 12:20–12:40 Presentation: Clinical Development And Progress Of siRNA Drugs In Cardiovascular/Metabolic Diseases 12:40–13:00 Presentation: Clinical Development And Progress Of siRNA Drugs In Non-Cardiovascular/Metabolic Diseases 13:00–14:00 Panel Discussion: Delivery Challenges And Design Optimization</p> | <p>Process Development And CMC 12:00–13:00 Bispecific ADC Process Development At IND And BLA Stages 13:00–14:00 Process Development Technology Innovation And Applications</p> | <p>Differentiated Target and Molecule Design ADC Innovative Targets & Technology Development From Preclinical To Clinical And Clinical Translation 13:00–13:20 Presentation: ADC Clinical R&D Differentiated Development 13:20–13:40 Presentation: ADC New Technology Applications And Clinical Translation 13:40–14:00 Presentation: ADC Clinical Development</p> |
| 14:00-15:00 | Networking & Events | Networking & Events | Commercial Manufacturing |
| 15:00-18:00 | <p>Process And Industrialization 15:00–16:00 Process Development And CMC Speakers: Xizhao Wang, CMC R&D, Rebo Biopharma 16:00–17:00 Analysis And Quality 17:00–18:00 Scale-Up Manufacturing</p> | <p>Differentiated Targets And Molecular Design Complex ADC Molecule Development 15:00–15:20 Presentation: ADC Development 15:20–15:40 Presentation: ADC Development 16:00–17:00 Panel Discussion: Bispecific/Multispecific ADC Differentiated Design, Linker-Payload Innovation And Global Collaboration</p> | 14:00–15:00 ADC Co-Line Production 15:00–16:00 ADC Segmented Production |

BIOCHINA2026 Antibody Drug Innovation Forum

BIOCHINA2026 Early Research & Discovery Forum

| Date | March 12th | March 13th | March 14th |
|-------------|--|---|---|
| 09:00-11:00 | Exhibition Hall Closed During Opening Ceremony | Bispecific/Multispecific Antibody Innovation 09:00-10:00 Panel Discussion: Exploration of Bispecific /Multispecific Antibody R&D and Clinical Development from a Global Innovation Collaboration Perspective Autoimmune 10:00-10:20 Presentation: TBC 10:20-10:40 Presentation: TBC | Early Research & Discovery 09:00-10:00 Early Research & Discovery 10:00-11:00 Early Research & Discovery |
| 11:00-12:00 | Lunch & Networking | Lunch & Networking | Lunch & Networking |
| 12:00-14:00 | Bispecific/Multispecific Antibody Innovation Bispecific Antibody Innovation and Clinical Development 12:00-12:20 Presentation: TBC 12:00-12:40 Presentation: Progress and Clinical Development of PD-1/VEGF Bispecific Antibodies 12:40-13:00 Presentation: TBC 13:00-14:00 Panel Discussion: TBC | Antibody Development & Clinical Research by Target 12:00-12:20 Presentation: Bispecific Antibody Design & Validation Antibody Development & Clinical Research by Indication | Early Research & Discovery 12:00-13:00 Early Research & Discovery 13:00-14:00 Early Research & Discovery |
| 14:00-15:00 | Networking & Events | Networking & Events | Early Research & Discovery 14:00-15:00 Early Research & Discovery 15:00-16:00 Early Research & Discovery |
| 15:00-18:00 | Bispecific/Multispecific Antibody Innovation Complex Molecule Innovation and Clinical Development 15:00-15:20 Presentation: Development of Novel NKCEs 15:20-15:40 Presentation: Preclinical Development of TCEs Multispecific Antibody Innovation and Clinical Development 16:00-16:20 Presentation: Trispecific TCEs | Upstream & Downstream Process Development and Optimization Antibody Process Development Case Focus 15:00-15:20 Presentation: TBC 15:20-15:40 Presentation: Considerations in Upstream Process Development for Antibodies 15:40-16:00 Presentation: Bispecific Antibody Process Development at IND Stage 16:00-17:00 Panel Discussion: Process Development and Lifecycle Management under Global Compliance 17:00-17:30 QbD-Driven Continuous Flow Process Validation and RTRT Implementation 17:30-18:00 Smart Scale-Up and PPQ Verification from Lab to Commercialization | |

| BIOCHINA2026 In Vivo CAR-T Innovation Forum | | BIOCHINA2026 In Vivo CAR-T Innovation Forum | BIOCHINA2026 Stem Cell Therapeutics Innovation Forum |
|---|---|--|--|
| Date | March 12th | March 13th | March 14th |
| 09:00-11:00 | Exhibition Hall Closed During Opening Ceremony 10:00-11:00 Opening Panel | Process & Quality 12:00-13:00 Panel Discussion: Nonclinical and CMC Considerations from IND Submission Perspective Process Development & Quality Analysis 13:00-13:20 Presentation: Selection and Process Development of In Vivo Cell Therapy Vectors 13:20-13:40 Presentation: Quality Standards for In Vivo CAR-T from a Regulatory Perspective 13:40-14:00 Presentation: Analytical Method Development and Quality Studies | iPSC Early Research Track 09:00-09:20 Presentation: Clinical Progress of iPSC Therapy for Heart Failure 09:20-09:40 Presentation: Cell Therapy for Parkinson's Disease – Clinical Validation of Next-Generation Therapies and Global Progress 09:40-10:00 Presentation: TBC 10:00-10:20 Presentation: Latest Clinical Progress of Fibroblast Therapy for DDD iPSC Process Challenges & Quality Control Track 11:20-11:40 Presentation: TBC 11:40-12:00 Presentation: TBC |
| 11:00-12:00 | Lunch & Networking | Lunch & Networking | Lunch & Networking |
| 12:00-14:00 | Clinical Development 09:00-10:00 Presentation: First-in-Human CAR-T Therapy for Multiple Myeloma – Clinical Practice and Insights 09:20-09:40 Presentation: From Hematologic Malignancies to Autoimmune Diseases 09:40-10:00 Presentation: Clinical Translation Prospects of LNPs and Non-Viral Vectors 10:00-10:20 Presentation: First-in-Human (FIH) Study Design 10:20-10:40 Presentation: IND Submission Pathways and Regulatory Considerations for In Vivo CAR-T 10:40-11:00 Presentation: Anticipating and Managing In Vivo CAR-T Safety | Commercialization 12:00-12:20 Presentation: Market Positioning and Clinical Value 12:20-12:40 Presentation: Insights from First-in-Human Clinical Data and Commercial Implications 12:40-13:00 Presentation: Innovative Pricing and Reimbursement Strategies for In Vivo CAR-T 13:00-13:20 Presentation: Market Access and Localization Strategies for In Vivo CAR-T in Emerging Markets 13:20-13:40 Presentation: Scale-Up Production and Supply Chain Challenges for In Vivo CAR-T 13:40-14:00 Presentation: IND Submission and Review Considerations for In Vivo CAR-T | MSC Development Track 12:00-12:20 Presentation: Phase III Clinical Trial Design of MSC for Knee Osteoarthritis 12:20-13:00 Panel Discussion: Clinical Design Considerations and Regulatory Standards for Knee Osteoarthritis 13:00-13:20 Presentation: Latest Progress and Quality Control of iMSC for Anti-Inflammation and Repair 13:20-13:40 Presentation: Gene-Modified MSC Therapy for Type 2 Diabetes – Latest Progress 13:40-14:00 Presentation: Clinical Progress and International Development Pathways of MSC Therapy for Acute Ischemic Stroke 14:00-14:20 Presentation: Latest Clinical Progress of MSC Therapy for Liver Cirrhosis 14:20-14:40 Presentation: Clinical Exploration of MSC Therapy for Liver Failure 14:40-15:00 Presentation: MSC Quality Control Strategies and Analytical Methods 15:00-16:00 Panel Discussion: Opportunities and Challenges for Stem Cell Drug Development under Regulation 818 |
| 14:00-15:00 | Networking & Events | Networking & Events | |
| 15:00-18:00 | Innovation & Development 15:00-16:00 Panel Discussion: In Vivo CAR-T R&D Progress and Development Prospects Speakers: 16:00-17:00 Lentiviral Vector In Vivo CAR-T R&D mRNA-LNP Delivery Vector In Vivo CAR-T R&D 17:00-17:20 Presentation: TBC 17:20-17:40 Presentation: TBC 17:40-18:00 Presentation: TBC | BIOCHINA2026 Stem Cell Therapeutics Innovation Forum <p>Stem Cell Industry Policies and Translational Practice</p> 15:00-15:20 Presentation: Regulatory Policies 15:20-15:40 Presentation: Lecheng Pilot Program 15:40-16:00 Presentation: Industrialization 16:00-16:20 Presentation: Drug Development for Autoimmune Diseases 16:20-16:40 Presentation: Drug Development for Nervous System Diseases 16:40-17:00 Presentation: Drug Development for Respiratory System Diseases 17:00-18:00 Panel Discussion: Bridging Technology, Clinical Practice, and Regulation – Pathways to Commercialization of Innovative Stem Cell Drugs | |

| BIOCHINA2026 Exosome Innovation Forum | | BIOCHINA2026 Cell Therapy Innovation Forum | BIOCHINA2026 Gene Therapy Innovation Forum |
|---------------------------------------|--|--|--|
| Date | March 12th | March 13th | March 14th |
| 09:00-11:00 | Exhibition Hall Closed During Opening Ceremony | Future Manufacturing 09:00–10:00 Panel Discussion: Choosing and Evaluating Future Commercialization Models 10:00–11:00 Cell Therapy Future Production Innovations Session Curator: Lin Youchen, WuXi AppTec MAH Production Lead Presentation: Decentralized / Bedside Manufacturing Presentation: Fast CAR-T Presentation: CMC Considerations for Global Registration | Indication Development 09:00-10:00 Panel Discussion: Impact of New Biomedical Technology Regulations on Gene Therapy 10:00–11:00 Case Studies in Gene Therapy Development for Rare Diseases |
| 11:00-12:00 | Lunch & Networking | Lunch & Networking | Lunch & Networking |
| 12:00-14:00 | Innovative R&D & Clinical Translation 12:00–13:00 Exosome Technology Innovation 13:00–14:00 Clinical Translation and Applications | Autoimmune Disease Drug Development 12:00–12:20 Presentation: Universal CAR-T 12:20–12:40 Presentation: Rapid Translation Strategies for Mature CAR-T Platforms 12:40–13:00 Presentation: Dual-Target CAR-T Development in Autoimmune Diseases 13:00–13:20 Presentation: Novel Therapies Using Natural Immune Cells 13:20–13:40 Presentation: Innovations in Regulatory Cell Therapy 13:40–14:00 Presentation: From Virus-Associated Tumors to Chronic Infections | Indication Development 12:00–13:00 Case Studies in Gene Therapy Development for Ophthalmic Diseases 13:00–14:40 Case Studies in Gene Therapy Development for Chronic Diseases |
| 14:00-15:00 | Networking & Events | Networking & Events | CMC and Regulatory Submission 14:40–15:00 Coordinated Development of Biomedical Technologies and Drug Submissions 15:00–16:00 Panel Discussion: CMC Development Requirements from IIT/Clinical Perspectives |
| 15:00-18:00 | Innovative R&D & Process Development 15:00–16:00 Case Studies in Innovative Development 16:00–17:00 Exosome Process Development 17:00–18:00 Scale-Up Manufacturing | Solid Tumor Drug Development 15:00–15:20 Presentation: Universal CAR-T 15:20–15:40 Presentation: Dual-Target CAR-T 15:40–16:00 Presentation: Ultra-Low Dose Metabolism-Enhanced Cell Therapy 16:00–16:20 Presentation: TCR-T Therapies 16:20–16:40 Presentation: Allogeneic TIL Therapy Based on Organoid Technology 16:40–17:00 Presentation: CAR-NK Therapies 17:00–18:00 Panel Discussion: Expanding Indications and Clinical Strategies for Cell Therapy | |

BIOCHINA2026 Biomanufacturing Industry Forum

| Date | March 12th | March 13th | March 14th |
|-------------|--|--|---|
| 09:00-11:00 | Exhibition Hall Closed During Opening Ceremony | Agricultural Innovation 09:00–10:00 Biostimulants, Straw Enzymatic Hydrolysis, and Synthetic Starch 10:00–11:00 Bio-Breeding, Microbial Fertilizers, and Sustainable Protein Production | Biosynthesis Technology 09:00–10:00 Enzyme Engineering and Metabolic Pathway Design 10:00–11:00 AI-Driven Design |
| 11:00-12:00 | Lunch & Networking | Lunch & Networking | Lunch & Networking |
| 12:00-14:00 | Biopharmaceutical Aesthetics 12:00–13:00 Renewable Materials and Bio-Based Alternatives 13:00–14:00 Extracellular Matrix and Functional Ingredients | Biopharmaceutical Aesthetics 12:00–13:00 Renewable Materials and Bio-Based Alternatives 13:00–14:00 Extracellular Matrix and Functional Ingredients | Biological Fermentation Technology 12:00–13:00 Pilot-Scale Upscaling 13:00–14:00 Continuous-Flow Fermentation |
| 14:00-15:00 | Networking & Events | Networking & Events | Gene Editing Technology 14:00–15:00 Gene Editing 15:00–16:00 Gene Editing |
| 15:00-18:00 | Food Development 15:00–16:00 Functional Additives 16:00–17:00 Cultured Meat and Fermented Dairy Products 17:00–18:00 Synthetic Proteins | Food Development 15:00–16:00 Functional Additives 16:00–17:00 Cultured Meat and Fermented Dairy Products 17:00–18:00 Synthetic Proteins | |

| BIOCHINA2026 AI Innovation Forum | | BIOCHINA2026 Peptide Drug Innovation Forum | BIOCHINA2026 Biomanufacturing Innovation Forum |
|----------------------------------|--|---|---|
| Date | | March 13th | March 14th |
| | Exhibition Hall Closed During Opening Ceremony | Long-Acting Peptide Development 09:00–10:20 Long-Acting Peptide Development 10:20–11:00 Panel Discussion: Future of Long-Acting Peptides and Other Formulations | Traditional Chinese Medicine 09:00-10:00 Cutting-Edge Technologies and Innovative Approaches 10:00-11:00 Biomanufacturing Development of Marine TCM and Special Microbial Resources |
| 11:00-12:00 | Lunch & Networking | Lunch & Networking | Lunch & Networking |
| 12:00-14:00 | AI-Powered Drug Discovery 12:00-13:00 Target Discovery and Disease Mechanism Analysis Using AI 13:00-14:00 Case Studies: AI-Driven Drug R&D | Clinical Development and Indication Selection 12:00–13:00 Panel Discussion: Clinical Development and Peptide Acceleration Strategies 13:00–14:00 Case Sharing: Clinical Indication Development for Peptide Drugs | New Drug Development 12:00-13:00 Cutting-Edge Technologies and Platform Building 13:00-14:00 Future Prospects of Industrial Translation |
| 14:00-15:00 | Networking & Events | Networking & Events | Energy 14:00-15:00 Innovative Approaches and Emerging Technologies in Bioenergy 15:00-16:00 Raw Materials, Processes, and System Integration |
| 15:00-18:00 | AI Automated Laboratories 15:00-16:00 Biological Automation Laboratory 16:00-17:00 Chemical Automation Laboratory 17:00-18:00 AI in Process Development and Optimization | GLP-1 Development 15:00–16:00 Panel Discussion: Next-Generation GLP-1 Development and Multi-Target Combinations 16:00–17:00 Key Considerations for Enhancing GLP-1 Safety Process Development & Manufacturing 17:00–18:00 Peptide Synthesis: Process Development and Manufacturing Essentials | |

About the Exhibition

BIOCHINA 2026 (11th Edition) will feature six exhibition halls—**Laboratory Instruments**, **Pharma Equipment**, **Raw Materials & Reagents**, **Consumables**, **International Services**, and **General Services**. Onsite, participants can connect directly with domestic and international brands, engage with founders and senior technology executives, and enhance business cooperation efficiency between exhibitors, end users, and distribution partners.

Laboratory Instruments Hall: Featuring analytical instruments, low-temperature storage, and automated/intelligent lab devices.

Pharma Equipment Hall: Showcasing bioreactors, solution preparation, chromatography & filtration systems, and packaging equipment.

Raw Materials & Reagents Hall: Covering full-process raw materials and reagents, including cell culture and assay reagents, and biopharmaceutical excipients.


Consumables Hall: Offering cell culture and purification consumables, packaging materials, and protective equipment.

International Service Hall – Technical Services & International Hall



- **Technical Services:** Includes CROs, CDMOs, engineering services, logistics & cold-chain, software solutions, and science parks.

- **International Pavilion:** Features country pavilions, overseas pharmaceutical companies, and upstream suppliers & service providers.

General Services: A one-stop industry hub integrating raw materials & reagents, consumables, Laboratory Instruments, Pharma Equipment, and technical services, connecting global premium brands and enterprises.



BIOCHINA Attendee Highlights




Pharma Company Distribution by Segment

Job Distribution

BiOPartnering offers **1-on-1, 30-minute meetings** to discuss cutting-edge technologies, innovative applications, and industry trends. Tailored to company needs, it facilitates investment, project deals, and strategic collaborations, promoting internationalization of the biotech industry and fostering global cooperation and win-win innovation.

At BIOCHINA 2025, private meeting rooms, Exclusive Reception Room and public discussion areas hosted **1,805 companies** from **28 countries and regions**, including Biotech, Pharma, MNCs, investors, and life science service providers, resulting in **2,679 meetings**.

For BIOCHINA 2026, the platform is further enhanced with a **VIP lounge**, alongside existing meeting spaces. **Over 2,000 companies** from **40+ countries and regions** are expected, with **3,000+ meetings** anticipated.



About Overseas

BIOCHINA 2026 is expected to attract participants from **40+ countries and regions**, including key markets such as South Korea, Russia, the United States, India, and Singapore. Companies from **Asia, Europe, the Americas, and Oceania** will actively engage in collaborations with the Chinese market. A wide range of participation formats will be offered, including international forums, **the International Hall, 1-on-1 BiOPartnering meetings, and networking receptions**, providing a comprehensive platform for companies to explore new business opportunities.

 ENMORE BIO


March 12-14, 2026 Suzhou International Expo Center

Dr Reddy Inceptua Group Pfizer Inc. Canada India
Certest Pharma AbTis, Co., Ltd. Daewon Pharm. Co. Ltd.
Binnopharm Group Celltrion, Inc. Belgium Laboratorios Bago S.A.
USA Lilly Russia Torrent Pharma PROMAMED Germany
Spain Novartis 100+ senior executives from France
global pharmaceutical companies Sweden

Sun Pharma Find Projects Daewoong Pharmaceutical GeroPharma
GL PharmTech Find Partnerships Insud Pharma Singapore Bayer
Thailand Pakistan Australia
United Kingdom Korea
Argentina Poland Pharmasyntez SENJU PHARMACEUTICAL





Join us at BIOCHINA2026



►► BIOCHINA ◀◀

Connecting Innovators, Enabling Bio-industry.
China's leading communication platform in Bio-industry



►► BioBD Group ◀◀



►► BIOCHINA GCD Group ◀◀
(Global Clinical Group)



►► WhatsApp Group ◀◀